GSK208141 + monophosphoryl lipid A–containing adjuvant

GSK208141 + monophosphoryl lipid A–containing adjuvant is a combination vaccine formulation composed of the investigational antigen GSK208141 and a monophosphoryl lipid A (MPL)-containing adjuvant. MPL is a detoxified derivative of lipopolysaccharide (LPS) from *Salmonella minnesota*, designed to reduce toxicity while retaining immunostimulatory activity. MPL functions as a Toll-like receptor 4 (TLR4) agonist, favoring a TRIF-biased signaling pathway. The addition of MPL to vaccine formulations enhances both humoral and cellular immune responses by stimulating innate immunity and promoting adaptive priming, especially cytotoxic T cell responses. MPL-containing adjuvants are used to achieve a robust immune response to the target antigen and have been incorporated into various vaccines evaluated for indications including infectious diseases and cancer. GSK208141 is a GSK (GlaxoSmithKline) code name, likely representing a recombinant protein or peptide antigen formulated specifically for use with MPL adjuvant[1][2][4].